Currently, more than 20 clinical trials testing anti-TIGIT agents (as single treatment or in combination with PD-(L)1 blockade) are launched by lead biopharmaceutical companies (such as Roche, BMS and Merck), including five phase 3 studies in solid cancers (glioblastoma, melanoma, lung, breast cancer, ...) and hematological malignancies (MM). Here, CD274 is linked to hematologic disorder.